Association between Smoking and p53 Mutation in Lung Cancer: A Meta-analysis

Clinical Oncology

Volumn 26, Issue 1, 2014, Pages 18-24

  Liu, X ^a   Lin, X J ^a   Wang, C P ^b   Yan, K K ^a   Zhao, L Y ^a   An, W X ^a   Liu, X D ^c  

^a JILIN UNIVERSITY   (China)

^b NORTHEAST NORMAL UNIVERSITY   (China)

^c Center for Radiological Research   (China)

Author keywords

Lung cancer; Meta analysis; P53 mutation; Smoking

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER PATIENT; CANCER RISK; DENATURING GRADIENT GEL ELECTROPHORESIS; DISEASE ASSOCIATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING;

LUNG CANCER; META-ANALYSIS; P53 MUTATION; SMOKING;

GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MUTATION; RISK FACTORS; SMOKING;

EID: 84890793083     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.09.003     Document Type: Article

References (45)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Tarver T. Cancer facts and figures 2012. American Cancer Society (ACS). JConsum Health Internet 2012, 16(3):366-367.
3. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
4. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
5. Wynder E.L., Graham E.A. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. JAm Med Assoc 1950, 143(4):329-336.
6. Tobacco use. Cancer facts and figures 2001 2001, 29-32. American Cancer Society, American Cancer Society, Atlanta, GA.
7. Schwartz A.G., Rothrock M., Yang P., Swanson G.M. Increased cancer risk among relatives of nonsmoking lung cancer cases. Genet Epidemiol 1999, 17(1):1-15.
8. Hartmann A., Blaszyk H., Saitoh S., et al. High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer 1996, 73(8):896-901.
9. Hartmann A., Rosanelli G., Blaszyk H., et al. Novel pattern of P53 mutation in breast cancers from Austrian women. JClin Invest 1995, 95(2):686-689.
10. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. JClin Oncol 1998, 16(3):1207-1217.
11. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327(7414):557-560.
12. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. JNatl Cancer Inst 1959, 22(4):719-748.
13. DerSimonian R., Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 2007, 28(2):105-114.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315(7109):629-634.
16. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
17. Friedrich J.O., Adhikari N.K., Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007, 7:5.
18. Sterne J.A.C., Bradburn M.J., Egger M. Meta-analysis in Stata™. Systematic reviews in health care: meta-analysis in context 2008, BMJPublishing Group, London, UK, http://dx.doi.org/10.1002/9780470693926.ch18. 2nd ed. M. Egger, G.D. Smith, D.G. Altman (Eds.).
19. Wang X., Christiani D.C., Wiencke J.K., et al. Mutations in the p53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epidemiol Biomarkers Prev 1995, 4(5):543-548.
20. Husgafvel-Pursiainen K., Kannio A. Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect 1996, 104(Suppl. 3):553-556.
21. Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y. Adose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. JSurg Oncol 1996, 61(1):20-26.
22. Esposito V., Baldi A., De Luca A., et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol 1997, 28(2):233-237.
23. Marchetti A., Pellegrini S., Sozzi G., et al. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer 1998, 78(1):73-78.
24. Gealy R., Zhang L., Siegfried J.M., Luketich J.D., Keohavong P. Comparison of mutations in the p53 and K-ras genes inlung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev 1999, 8(4 Pt 1):297-302.
25. Ahrendt S.A., Chow J.T., Yang S.C., et al. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res 2000, 60(12):3155-3159.
26. Husgafvel-Pursiainen K., Boffetta P., Kannio A., et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 2000, 60(11):2906-2911.
27. Vahakangas K.H., Bennett W.P., Castren K., et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001, 61(11):4350-4356.
28. Hwang S.J., Cheng L.S.C., Lozano G., Amos C.I., Gu X.J., Strong L.C. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003, 113(3):238-243.
29. Mechanic L.E., Marrogi A.J., Welsh J.A., et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005, 26(3):597-604.
30. Hagiwara N., Mechanic L.E., Trivers G.E., et al. Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res 2006, 66(16):8309-8317.
31. Mounawar M., Mukeria A., Le Calvez F., et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007, 67(12):5667-5672.
32. Ludovini V., Pistola L., Gregorc V., et al. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the Perugia multidisciplinary team for thoracic oncology. JThorac Oncol 2008, 3(4):365-373.
33. Kosaka T., Yatabe Y., Onozato R., Kuwano H., Mitsudomi T. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. JThorac Oncol 2009, 4(1):22-29.
34. Le Calvez F., Mukeria A., Hunt J.D., et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res 2005, 65(12):5076-5083.
35. Knudson A.G. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993, 90(23):10914-10921.
36. Mulshine J.L., Treston A.M., Brown P.H., Birrer M.J., Shaw G.L. Initiators and promoters of lung cancer. Chest 1993, 103(Suppl. 1):4S-11S.
37. Rodin S.N., Rodin A.S. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci USA 2000, 97(22):12244-12249.
38. Baan R., Grosse Y., Straif K., et al. Special report: policy: a review of human carcinogens-Part F: chemical agents and related occupations. Lancet Oncol 2009, 10(12):1143-1144.
39. Baird W.M., Hooven L.A., Mahadevan B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts and mechanism of action. Environ Mol Mutagen 2005, 45(2-3):106-114.
40. Labib S., Yauk C., Williams A., et al. Subchronic oral exposure to benzo(a)pyrene leads to distinct transcriptomic changes in the lungs that are related to carcinogenesis. Toxicol Sci 2012, 129(1):213-224.
41. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspect Biol 2010, 2(1):1-17.
42. Hainaut P., Pfeifer G.P. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001, 22(3):367-374.
43. Devi K.P., Sivamaruthi B., Kiruthiga P.V., Pandian S.K. Study of p53 codon 72 polymorphism and codon 249 mutations in Southern India in relation to age, alcohol drinking and smoking habits. Hum Exp Toxicol 2010, 29(6):451-458.
44. Anna L., Holmila R., Kovacs K., et al. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary. Mutagenesis 2009, 24(6):475-480.
45. Wang B., Zhang Y., Xu D., et al. Meta-analysis on the relationship between tobacco smoking, alcohol drinking and p53 alteration in cases with esophageal carcinoma. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25(9):775-778.